Extract of Cordyceps militaris inhibits angiogenesis and suppresses tumor growth of human malignant melanoma cells

Ruma,I.  Made Winarsa; Putranto,Endy Widya; Kondo,Eisaku; Watanabe,Risayo; Saito,Ken; Inoue,Yusuke; Yamamoto,Ken-Ichi; Nakata,Susumu; Kaihata,Masaji; Murata,Hitoshi; Sakaguchi,Masakiyo

doi:10.3892/ijo.2014.2397

Extract of Cordyceps militaris inhibits angiogenesis and suppresses tumor growth of human malignant melanoma cells

Authors:
- I. Made Winarsa Ruma
- Endy Widya Putranto
- Eisaku Kondo
- Risayo Watanabe
- Ken Saito
- Yusuke Inoue
- Ken-Ichi Yamamoto
- Susumu Nakata
- Masaji Kaihata
- Hitoshi Murata
- Masakiyo Sakaguchi
View Affiliations

Affiliations: Department of Cell Biology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan, Division of Oncological Pathology, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya 464-8681, Japan, Faculty of Science and Technology, Division of Molecular Science, Gunma University, Kiryu, Gunma 376-8515, Japan, CAITAC Corporation, Kita-ku, Okayama 700-8586, Japan
Published online on: April 24, 2014 https://doi.org/10.3892/ijo.2014.2397
Pages: 209-218

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiogenesis is essential for tumor development and metastasis. Among several angiogenic factors, vascular endothelial growth factor receptor (VEGF) is important for tumor-derived angiogenesis and commonly overexpressed in solid tumors. Thus, many antitumor strategies targeting VEGF have been developed to inhibit cancer angiogenesis, offering insights into the successful treatment of solid cancers. However, there are a number of issues such as harmful effects on normal vascularity in clinical trials. Taking this into consideration, we employed Cordyceps militaris as an antitumor approach due to its biological safety in vivo. The herbal medicinal mushroom Cordyceps militaris has been reported to show potential anticancer properties including anti-angiogenic capacity; however, its concrete properties have yet to be fully demonstrated. In this study, we aimed to elucidate the biological role of Cordyceps militaris extract in tumor cells, especially in regulating angiogenesis and tumor growth of a human malignant melanoma cell line. We demonstrated that Cordyceps militaris extract remarkably suppressed tumor growth via induction of apoptotic cell death in culture that links to the abrogation of VEGF production in melanoma cells. This was followed by mitigation of Akt1 and GSK-3β activation, while p38α phosphorylation levels were increased. Extract treatment in mouse model xenografted with human melanoma cells resulted in a dramatic antitumor effect with downregulation of VEGF expression. The results suggest that suppression of tumor growth by Cordyceps militaris extract is, at least, mediated by its anti-angiogenicity and apoptosis induction capacities. Cordyceps militaris extract may be a potent antitumor herbal drug for solid tumors.

View Figures

View References

1.	Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI
2.	Dewing D, Emmett M and Pritchard Jones R: The roles of angiogenesis in malignant melanoma: trends in basic science research over the last 100 years. ISRN Oncol. 2012:5469272012.PubMed/NCBI
3.	Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol. 29:15–18. 2002. View Article : Google Scholar : PubMed/NCBI
4.	Zetter BR: Angiogenesis and tumor metastasis. Annu Rev Med. 49:407–424. 1998. View Article : Google Scholar : PubMed/NCBI
5.	Naumov GN, Bender E, Zurakowski D, et al: A model of human tumor dormancy: an angiogenic switch from the non-angiogenic phenotype. J Natl Cancer Inst. 98:316–325. 2006. View Article : Google Scholar : PubMed/NCBI
6.	Nanus DM, Schmitz-Dräger BJ, Motzer RJ, et al: Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst. 85:1597–1599. 1993. View Article : Google Scholar : PubMed/NCBI
7.	Toi M, Hoshina S, Takayanagi T and Tominaga T: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res. 85:1045–1048. 1994. View Article : Google Scholar : PubMed/NCBI
8.	Relf M, LeJeune S, Scott PA, et al: Expression of the angiogenic factors, vascular endothelial growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet derived growth endothelial cell growth factor, placental growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 57:963–969. 1997.
9.	Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J and Hanahan D: Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell. 66:1095–1104. 1991. View Article : Google Scholar : PubMed/NCBI
10.	Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
11.	Ferrara N: Vascular endothelial growth factor. Eur J Cancer. 32A:2413–2422. 1996. View Article : Google Scholar : PubMed/NCBI
12.	Risau W: Mechanisms of angiogenesis. Nature. 386:671–674. 1997. View Article : Google Scholar : PubMed/NCBI
13.	Shibuya M: Vascular endothelial growth factor-dependent and independent regulation of angiogenesis. BMB Rep. 41:278–286. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Benjamin LE and Keshet E: Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA. 94:8761–8766. 1997. View Article : Google Scholar : PubMed/NCBI
15.	Shibuya M: Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 39:469–478. 2006. View Article : Google Scholar : PubMed/NCBI
16.	Ellis LM and Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 8:579–591. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 20:4368–4380. 2002. View Article : Google Scholar
18.	Erhard H, Rietveld FJ, van Altena MC, Bröcker EB, Ruiter DJ and de Waal RM: Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis. Melanoma Res. 7(Suppl 2): S19–S26. 1997. View Article : Google Scholar : PubMed/NCBI
19.	Bergers G and Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603. 2008. View Article : Google Scholar : PubMed/NCBI
20.	Potente M, Gerhardt H and Carmeliet P: Basic and therapeutic aspects of angiogenesis. Cell. 146:873–887. 2011. View Article : Google Scholar : PubMed/NCBI
21.	Cunningham KG, Hutchinson SA, Manson W and Spring FS: Cordycepin, a metabolic product from cultures of C. militaris (Linn.) Link Part I Isolation and characterisation. J Chem Soc. 508:2299–3200. 1951. View Article : Google Scholar
22.	Song CH, Jeon YJ, Yang BK, Ra KS and Sung JM: Anti-complementary activity of exo-polymers produced from submerged mycelial cultures of higher fungi with particular reference to Cordyceps militaris. J Microbiol Biotechnol. 8:536–539. 1998.
23.	Mizuno T: Medicinal effects and utilization of Cordyceps (Fr.) Link (Ascomycetes) and Isaria Fr (Mitosporic Fungi) Chinese caterpillar fungi, ‘Tochukaso’ (Review). Int J Med Mushroom. 1:251–261. 1999.
24.	Nag TB and Wang HX: Pharmacological actions of Cordyceps, a prized folk medicine. J Pharm Pharmacol. 57:1509–1519. 2005. View Article : Google Scholar
25.	Das SK, Masuda M, Hatashita M, Sakurai A and Sakakibara M: A new approach for improving cordycepin productivity in surface liquid culture of C. militaris using high-energy ion beam irradiation. Lett Appl Microbiol. 47:534–538. 2008. View Article : Google Scholar : PubMed/NCBI
26.	Das SK, Masuda M, Sakurai A and Sakakibara M: Medicinal uses of the mushroom Cordyceps militaris: current state and prospects. Fitoterapia. 8:961–968. 2010.PubMed/NCBI
27.	Sakaguchi M, Huh N and Namba M: A novel tumor suppressor, REIC/Dkk-3 gene identified by our in vitro transformation model of normal human fibroblasts works as a potent therapeutic antitumor agent. Adv Exp Med Biol. 720:209–215. 2012. View Article : Google Scholar
28.	Das SK, Masuda M, Hatashita M, Sakurai A and Sakakibara M: Optimization of culture medium for cordycepin production using C. militaris mutant obtained by ion beam irradiation. Proc Biochem. 45:129–132. 2010. View Article : Google Scholar
29.	Graupera M and Potente M: Regulation of angiogenesis by PI3K signaling networks. Exp Cell Res. 319:1348–1355. 2013. View Article : Google Scholar : PubMed/NCBI
30.	Graupera M, Guillermet-Guibert J, Foukas LC, et al: Angiogenesis selectively requires the p110 alpha isoform of PI3K to control endothelial cell migration. Nature. 453:662–666. 2008. View Article : Google Scholar : PubMed/NCBI
31.	Wang F, Yamauchi M, Muramatsu M, Osawa T, Tsuchid R and Shibuya M: MRACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3K/Akt pathway. J Biol Chem. 286:9097–9106. 2011. View Article : Google Scholar
32.	Zhao P, Meng Q, Liu LZ, You YP, Liu N and Jiang BH: Regulation of survivin by PI3K/Akt/p70S6K1 pathway. Biochem Biophys Res Commun. 395:219–224. 2010. View Article : Google Scholar : PubMed/NCBI
33.	Maity A, Pore N, Lee J, Solomon D and O’Rourke DM: Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3-kinase and distinct from that induced by hypoxia. Cancer Res. 60:5879–5886. 2000.
34.	Zhong H, Chiles K, Feldse D, et al: Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60:1541–1545. 2000.
35.	Karar J and Maity A: PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 4:512011. View Article : Google Scholar : PubMed/NCBI
36.	Grimes CA and Jope RS: The multifaceted roles of glycogen synthase kinase 3β in cellular signaling. Prog Neurobiol. 65:391–426. 2001.
37.	Forde JE and Dale TC: Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci. 64:1930–1944. 2007. View Article : Google Scholar : PubMed/NCBI
38.	Rayasam GV, Tulasi VK, Sodhi R, Davis JA and Ray A: Glycogen synthase kinase 3: more than a namesake. Br J Pharmacol. 156:885–898. 2009. View Article : Google Scholar : PubMed/NCBI
39.	Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K and Peters GJ: Molecular pathways involved in the synergistic interaction of the PKCβ inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer. 99:750–759. 2008.
40.	Graff JR, McNulty AM, Hanna KR, et al: The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 65:7462–7469. 2005. View Article : Google Scholar
41.	Hanauske AR, Oberschmidt O, Hanauske-Abel H, Lahn MM and Eismann U: Antitumor activity of enzastaurin (LY317615.HCl) against human cancer cell lines and freshly explanted tumors investigated in in-vitro (corrected) soft-agar cloning experiments. Invest New Drugs. 25:205–210. 2007. View Article : Google Scholar
42.	Lee KW, Kim SG, Kim HP, et al: Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res. 68:1916–1926. 2008. View Article : Google Scholar : PubMed/NCBI
43.	Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell. 129:1261–1274. 2007. View Article : Google Scholar : PubMed/NCBI
44.	Kandel ES and Hay N: The regulation and activities of the multi-functional serine/threonine kinase Akt/PKB. Exp Cell Res. 253:210–229. 1999. View Article : Google Scholar : PubMed/NCBI
45.	Chen J, Somanath PR, Razorenova OV, Chen WS, Hay N, Bornstein P and Byzova TV: Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nature Med. 11:1188–1196. 2005. View Article : Google Scholar : PubMed/NCBI
46.	Somanath PR, Razorenova OV, Chen J and Byzova TV: Akt1 in Endothelial cell and angiogenesis. Cell Cycle. 5:512–518. 2006. View Article : Google Scholar : PubMed/NCBI
47.	Ruoslahti E and Engvall E: Integrins and vascular extracellular matrix assembly. J Clin Invest. 99:1149–1152. 1997. View Article : Google Scholar : PubMed/NCBI
48.	Carmeliet P, Moons L, Luttun A, et al: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 7:575–583. 2001. View Article : Google Scholar
49.	Luangdilok S, Box C, Harrington K, Rhys-Evans P and Eccles S: MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cellcarcinoma of the head and neck. Eur J Cancer. 47:520–529. 2011. View Article : Google Scholar : PubMed/NCBI
50.	Kyriakis JM and Avruch J: Sounding the alarm: Protein kinase cascades activated by stress and inflammation. J Biol Chem. 271:24313–24316. 1996. View Article : Google Scholar : PubMed/NCBI
51.	Conrad PW, Rust RT, Han J, Millhorn DE and Beitner-Johnson D: Selective activation of p38alpha and p38gamma by hypoxia. Role in regulation of cyclin D1 by hypoxia in PC12 cells. J Biol Chem. 274:23570–23576. 1999. View Article : Google Scholar : PubMed/NCBI
52.	Lai WC, Zhou M, Shankavaram U, Peng G and Wahl LM: Differential regulation of lipopolysaccharide induced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. J Immunol. 170:6244–6249. 2003. View Article : Google Scholar
53.	Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 270:1326–1331. 1995. View Article : Google Scholar : PubMed/NCBI
54.	De S, Razorenova O, McCabe NP, O’Toole T, Qin J and Byzova TV: VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci USA. 102:7589–7594. 2005. View Article : Google Scholar : PubMed/NCBI
55.	Franco CA, Liebner S and Gerhardt H: Vascular morphogenesis: a Wnt for every vessel? Curr Opin Genet Dev. 19:476–483. 2009. View Article : Google Scholar : PubMed/NCBI
56.	Fischer C, Mazzone M, Jonckx B and Carmeliet P: FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nature Rev Cancer. 8:942–956. 2008. View Article : Google Scholar : PubMed/NCBI